Exelixis, Inc. (0IJO.L)
USD 35.79
(3.5%)
USD 35.79
(3.5%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 207.76 Million USD | 13.98% |
| 2022 | 182.28 Million USD | -21.11% |
| 2021 | 231.06 Million USD | 106.71% |
| 2020 | 111.78 Million USD | -65.18% |
| 2019 | 321.01 Million USD | -53.48% |
| 2018 | 690.07 Million USD | 347.44% |
| 2017 | 154.22 Million USD | 319.63% |
| 2016 | -70.22 Million USD | 58.63% |
| 2015 | -169.73 Million USD | 36.79% |
| 2014 | -268.54 Million USD | -9.72% |
| 2013 | -244.76 Million USD | -65.78% |
| 2012 | -147.64 Million USD | -295.05% |
| 2011 | 75.69 Million USD | 181.99% |
| 2010 | -92.33 Million USD | 31.72% |
| 2009 | -135.22 Million USD | 16.97% |
| 2008 | -162.85 Million USD | -88.53% |
| 2007 | -86.38 Million USD | 14.89% |
| 2006 | -101.49 Million USD | -20.25% |
| 2005 | -84.4 Million USD | 38.5% |
| 2004 | -137.24 Million USD | -44.81% |
| 2003 | -94.77 Million USD | -10.04% |
| 2002 | -86.13 Million USD | -20.99% |
| 2001 | -71.18 Million USD | 5.48% |
| 2000 | -75.31 Million USD | -302.73% |
| 1999 | -18.7 Million USD | -19.37% |
| 1998 | -15.66 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 226.11 Million USD | 505.93% |
| 2024 Q3 | 117.97 Million USD | -47.83% |
| 2024 Q1 | 37.31 Million USD | -56.36% |
| 2023 FY | 207.76 Million USD | 13.98% |
| 2023 Q3 | 1.04 Million USD | -98.72% |
| 2023 Q2 | 81.17 Million USD | 102.8% |
| 2023 Q1 | 40.02 Million USD | 232.66% |
| 2023 Q4 | 85.51 Million USD | 8114.99% |
| 2022 Q2 | 70.67 Million USD | 3.06% |
| 2022 Q1 | 68.57 Million USD | -27.94% |
| 2022 Q3 | 73.21 Million USD | 3.59% |
| 2022 Q4 | -30.17 Million USD | -141.21% |
| 2022 FY | 182.28 Million USD | -21.11% |
| 2021 FY | 231.06 Million USD | 106.71% |
| 2021 Q1 | 1.6 Million USD | -94.36% |
| 2021 Q2 | 96.09 Million USD | 5902.0% |
| 2021 Q4 | 95.16 Million USD | 149.1% |
| 2021 Q3 | 38.2 Million USD | -60.24% |
| 2020 Q2 | 66.82 Million USD | 37.46% |
| 2020 Q3 | -32.04 Million USD | -147.95% |
| 2020 Q4 | 28.38 Million USD | 188.6% |
| 2020 FY | 111.78 Million USD | -65.18% |
| 2020 Q1 | 48.61 Million USD | -29.28% |
| 2019 Q1 | 75.77 Million USD | -78.96% |
| 2019 FY | 321.01 Million USD | -53.48% |
| 2019 Q4 | 68.74 Million USD | -29.46% |
| 2019 Q3 | 97.45 Million USD | 23.29% |
| 2019 Q2 | 79.04 Million USD | 4.31% |
| 2018 Q1 | 115.85 Million USD | 201.01% |
| 2018 FY | 690.07 Million USD | 347.44% |
| 2018 Q4 | 360.08 Million USD | 184.36% |
| 2018 Q3 | 126.63 Million USD | 44.73% |
| 2018 Q2 | 87.49 Million USD | -24.48% |
| 2017 Q4 | 38.48 Million USD | -52.71% |
| 2017 Q1 | 16.7 Million USD | -52.45% |
| 2017 FY | 154.22 Million USD | 319.63% |
| 2017 Q3 | 81.38 Million USD | 360.93% |
| 2017 Q2 | 17.65 Million USD | 5.72% |
| 2016 Q3 | -11.28 Million USD | 69.52% |
| 2016 Q1 | -61.34 Million USD | -40.57% |
| 2016 FY | -70.22 Million USD | 58.63% |
| 2016 Q4 | 35.12 Million USD | 411.26% |
| 2016 Q2 | -37.01 Million USD | 39.66% |
| 2015 Q2 | -43.36 Million USD | -23.29% |
| 2015 FY | -169.73 Million USD | 36.79% |
| 2015 Q4 | -43.64 Million USD | 8.25% |
| 2015 Q3 | -47.56 Million USD | -9.69% |
| 2015 Q1 | -35.17 Million USD | 39.31% |
| 2014 FY | -268.54 Million USD | -9.72% |
| 2014 Q4 | -57.95 Million USD | 7.36% |
| 2014 Q3 | -62.56 Million USD | 14.78% |
| 2014 Q2 | -73.41 Million USD | 1.62% |
| 2014 Q1 | -74.61 Million USD | -5.47% |
| 2013 FY | -244.76 Million USD | -65.78% |
| 2013 Q4 | -70.74 Million USD | -5.4% |
| 2013 Q3 | -67.12 Million USD | -7.98% |
| 2013 Q2 | -62.16 Million USD | -38.97% |
| 2013 Q1 | -44.72 Million USD | 14.3% |
| 2012 Q4 | -52.19 Million USD | -59.06% |
| 2012 FY | -147.64 Million USD | -295.05% |
| 2012 Q1 | -26.15 Million USD | -156.49% |
| 2012 Q2 | -36.48 Million USD | -39.52% |
| 2012 Q3 | -32.81 Million USD | 10.07% |
| 2011 Q4 | 46.29 Million USD | -40.54% |
| 2011 FY | 75.69 Million USD | 181.99% |
| 2011 Q3 | 77.86 Million USD | 471.23% |
| 2011 Q2 | -20.97 Million USD | 23.7% |
| 2011 Q1 | -27.49 Million USD | -53.88% |
| 2010 Q2 | -22.61 Million USD | 47.71% |
| 2010 Q4 | -17.86 Million USD | -107.66% |
| 2010 Q3 | -8.6 Million USD | 61.96% |
| 2010 Q1 | -43.24 Million USD | -49.99% |
| 2010 FY | -92.33 Million USD | 31.72% |
| 2009 Q1 | -36.18 Million USD | 4.66% |
| 2009 Q4 | -28.83 Million USD | -13.32% |
| 2009 Q3 | -25.44 Million USD | 43.15% |
| 2009 Q2 | -44.76 Million USD | -23.72% |
| 2009 FY | -135.22 Million USD | 16.97% |
| 2008 Q2 | -45.12 Million USD | -9.33% |
| 2008 Q1 | -41.27 Million USD | -107.18% |
| 2008 FY | -162.85 Million USD | -88.53% |
| 2008 Q4 | -37.94 Million USD | 1.45% |
| 2008 Q3 | -38.5 Million USD | 14.67% |
| 2007 Q4 | -19.92 Million USD | -45.46% |
| 2007 Q2 | -28.56 Million USD | -18.02% |
| 2007 Q1 | -24.2 Million USD | 3.9% |
| 2007 FY | -86.38 Million USD | 14.89% |
| 2007 Q3 | -13.69 Million USD | 52.05% |
| 2006 Q1 | -27.12 Million USD | -10.61% |
| 2006 Q4 | -25.18 Million USD | 0.06% |
| 2006 Q3 | -25.19 Million USD | -5.03% |
| 2006 Q2 | -23.99 Million USD | 11.55% |
| 2006 FY | -101.49 Million USD | -20.25% |
| 2005 Q3 | -22.77 Million USD | -134.89% |
| 2005 Q1 | -27.41 Million USD | 47.21% |
| 2005 Q4 | -24.52 Million USD | -7.67% |
| 2005 FY | -84.4 Million USD | 38.5% |
| 2005 Q2 | -9.69 Million USD | 64.63% |
| 2004 Q3 | -27.18 Million USD | 7.18% |
| 2004 Q2 | -29.29 Million USD | -1.55% |
| 2004 FY | -137.24 Million USD | -44.81% |
| 2004 Q1 | -28.84 Million USD | -23.9% |
| 2004 Q4 | -51.92 Million USD | -90.97% |
| 2003 Q1 | -23.05 Million USD | -10.52% |
| 2003 Q2 | -23.44 Million USD | -1.67% |
| 2003 Q3 | -24.99 Million USD | -6.62% |
| 2003 FY | -94.77 Million USD | -10.04% |
| 2003 Q4 | -23.27 Million USD | 6.87% |
| 2002 Q1 | -18.42 Million USD | -0.83% |
| 2002 Q4 | -20.86 Million USD | 9.07% |
| 2002 FY | -86.13 Million USD | -20.99% |
| 2002 Q3 | -22.94 Million USD | 4.02% |
| 2002 Q2 | -23.9 Million USD | -29.76% |
| 2001 Q3 | -16.49 Million USD | 30.45% |
| 2001 Q2 | -23.7 Million USD | -86.4% |
| 2001 Q1 | -12.71 Million USD | 73.53% |
| 2001 Q4 | -18.26 Million USD | -10.79% |
| 2001 FY | -71.18 Million USD | 5.48% |
| 2000 Q4 | -48.05 Million USD | -433.97% |
| 2000 Q1 | -7.28 Million USD | 0.0% |
| 2000 Q2 | -10.97 Million USD | -50.57% |
| 2000 FY | -75.31 Million USD | -302.73% |
| 2000 Q3 | -8.99 Million USD | 17.98% |
| 1999 FY | -18.7 Million USD | -19.37% |
| 1998 FY | -15.66 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Thermo Fisher Scientific Inc. | 5.99 Billion USD | 96.534% |
| Dynavax Technologies Corporation | -6.38 Million USD | 3351.917% |
| Illumina, Inc. | -1.16 Billion USD | 117.895% |
| IQVIA Holdings Inc. | 1.35 Billion USD | 84.701% |
| Biogen Inc. | 1.16 Billion USD | 82.106% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | 146.79% |
| Mettler-Toledo International Inc. | 788.77 Million USD | 73.66% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | 138.764% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | -15687.614% |
| Waters Corporation | 642.23 Million USD | 67.65% |
| Perrigo Company plc | -12.7 Million USD | 1735.945% |
| uniQure N.V. | -308.47 Million USD | 167.352% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | 159.009% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | 237.063% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | 175.243% |
| bluebird bio, Inc. | -211.91 Million USD | 198.043% |
| Cara Therapeutics, Inc. | -118.51 Million USD | 275.31% |
| Imunon, Inc. | -19.51 Million USD | 1164.644% |
| Myriad Genetics, Inc. | -112 Million USD | 285.504% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 16.794% |
| Nektar Therapeutics | -276.05 Million USD | 175.262% |
| Editas Medicine, Inc. | -153.21 Million USD | 235.6% |
| Verastem, Inc. | -87.36 Million USD | 337.807% |
| Walgreens Boots Alliance, Inc. | -8.63 Billion USD | 102.406% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | 565.806% |
| Heron Therapeutics, Inc. | -110.55 Million USD | 287.922% |
| Unity Biotechnology, Inc. | -39.86 Million USD | 621.237% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | -23.932% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | 180.582% |
| Evolus, Inc. | -61.68 Million USD | 436.816% |
| Adicet Bio, Inc. | -142.65 Million USD | 245.639% |
| Aclaris Therapeutics, Inc. | -88.48 Million USD | 334.813% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 94.745% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | 199.291% |
| FibroGen, Inc. | -284.23 Million USD | 173.097% |
| Agilent Technologies, Inc. | 1.24 Billion USD | 83.245% |
| OPKO Health, Inc. | -188.86 Million USD | 210.008% |
| Homology Medicines, Inc. | -53.74 Million USD | 486.59% |
| Geron Corporation | -184.12 Million USD | 212.838% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | 147.193% |
| Viking Therapeutics, Inc. | -85.89 Million USD | 341.883% |
| Anavex Life Sciences Corp. | -47.5 Million USD | 537.354% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | 143.177% |
| Zoetis Inc. | 2.34 Billion USD | 91.136% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | 186.844% |
| Abeona Therapeutics Inc. | -54.18 Million USD | 483.415% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | 94.26% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | 592.346% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | 156.722% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | -95.746% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | 26.218% |
| Blueprint Medicines Corporation | -506.98 Million USD | 140.981% |
| Insmed Incorporated | -749.56 Million USD | 127.718% |
| TG Therapeutics, Inc. | 12.67 Million USD | -1539.56% |
| Incyte Corporation | 597.59 Million USD | 65.233% |
| Emergent BioSolutions Inc. | -760.5 Million USD | 127.32% |